Please enter the information you want to find
Hot key words：
The core business of Shanghai Bao Pharmaceuticals Co., Ltd. involves the industrialization and commercialization of recombinant protein and antibody drugs. We are currently constructing a modern biopharmaceutical industrial base in Luodian Industrial Park, Baoshan District, Shanghai, which meets GMP requirements. The total investment exceeds 900 million RMB. The base is planned to include multiple primary production lines for mammalian and E. coli/yeast expression systems, covering aseptic injection, lyophilized powder injection, and single-use pre-filled dosage vials.
Since
2011
Clinical trial success rate
66.6
%
R&D investment
33.3
%
In August 2011, Suzhou Kangju Biotechnology Co., Ltd. (“Kangju”) was established in Suzhou Industrial Park, focusing on the development of recombinant enzyme drugs and monoclonal antibodies.
In July 2014, Suzhou Centergene Pharmaceuticals Co., Ltd. (“Shengji”) was established in Suzhou Industrial Park, focusing on development of glycoprotein-based drugs (pipeline for assisted reproduction).
In December 2019, Shanghai Bao Pharmaceuticals Co., Ltd. was established in Luodian Industrial Park, Baoshan District, Shanghai. Bao Pharma integrated Kangju and Shengji, took over existing projects and promoted their industrialization process.
In March 2021, a Series A financing of 474 million RMB was completed.
In October 2021, the acquisition of the land (94 acres) and factory building (25,000 square meters) located at 50 Luoxin Road from Shanghai Jingfeng Pharmaceutical Co., Ltd. was completed, which empowered Bao Pharma with the capability for industrial production of biopharmaceuticals.
In August 2022, a Series B financing of 585 million RMB was completed.
In December 2022, Bao Pharma obtained the Drug Manufacturing License issued by the Shanghai Administration of Pharmaceuticals and Medical Devices for the production of therapeutic biological products (recombinant human hyaluronidase for injection).
In May 2023, Bao Pharma obtained the Drug Manufacturing License issued by the Shanghai Administration of Pharmaceuticals and Medical Devices, authorizing for the production of recombinant human follicle-stimulating hormone-CTP (FSH-CTP) fusion protein. It was developed by its subsidiary Shengji.
In December 2023, the same FSH-CTP product was submitted to the National Medical Products Administration for market launch application.
In July 2024, Bao Pharma submitted an application to the National Medical Products Administration for the market launch of its recombinant human hyaluronidase for injection.
